What is the Phoenix Mobile App?
The Phoenix Mobile App is a dedicated health hub for APOE4 carriers launched in beta for iOS and Android. It combines bloodwork tracking, wearable data integration with Apple Health and Google Health, and daily check-ins where members log interventions and life events like late dinners, alcohol, travel, and supplements. The app uses this data to surface personalized insights like the impact of magnesium glycinate on sleep scores or ezetimibe on LDL cholesterol, and aggregates community data to identify the highest-impact levers for each members goals.
What is ALZ-801 and why does it matter for APOE4 carriers?
ALZ-801, also called valiltramiprosate, is one of the first drugs developed specifically for APOE4 carriers rather than the general Alzheimer population. The APOLLOE4 Phase 3 trial reported results that Phoenix members dissected collectively, debating whether it could be the preventive drug APOE4 carriers have been waiting for. Because the drug targets APOE4-specific disease mechanisms, it represents a potential shift toward precision Alzheimer therapeutics for the highest-genetic-risk population.
What device studies did Phoenix run in January?
Two device studies were active in January. The Neuronic ZenoWell photobiomodulation study wrapped up its active phase with members tracking outcomes and sharing honest feedback, including both benefits and side effects like dry mouth. The Sens.ai neurofeedback helmet study launched during the same period. These are structured medtech partnerships where Phoenix members get early access to devices and contribute to real-world evidence. The first partnership enrolled 45 members in 5 days against a target of 30 in 2 weeks.
What biomarker improvements do engaged Phoenix members see?
Over 3 to 6 months, engaged Phoenix members showed meaningful biomarker improvements: ApoB down about 15 percent, HbA1c down about 8 percent, and body fat down about 12 percent. These are actual member numbers rather than hypotheticals. The improvements reflect the combination of personalized bloodwork interpretation, community accountability, structured goal setting, and targeted interventions that are tracked and iterated based on real data rather than generic advice.
What topics were Phoenix members researching in January?
Members discussed Obicetrapib (a cholesterol drug with APOE4-relevant implications), a critical read of a new Bredesen ReCODE Protocol clinical trial paper, CRISPR 2.0 implications for APOE4 gene editing, the creation of USCs new APOE4/4 research department, rapamycin, selegiline, omega-3 LPC-DHA, plant sterols, and alpha-ketoglutarate. Beyond breakthroughs, members also tackled niche APOE4 questions like anesthesia risks, gas stove exposure, tattoo safety, and whether pink noise actually helps sleep.
So Why Aren't You Here Yet?
Look. You can keep piecing together Alzheimer's prevention advice from Reddit threads, random podcasts, and Dr. Google. Or you can join the only community built specifically for APOE4 carriers. By an APOE4/4 carrier. With real data, real experiments, real partnerships, and real people who understand exactly what you're going through. January alone had 82 posts of science, support, and action. February is already underway. Join the Phoenix Community → The question isn't whether you can afford to join. It's whether you can afford to keep missing this. Most Newsletters? One-way street. How boring… This is the Phoenix Community. So let's make it a two-way street. Got a question? Feedback? Hit reply. I read every single one. The Phoenix Community is a private, science-driven membership for APOE4 carriers and anyone serious about Alzheimer's prevention. Founded by Dr. Kevin Tran (APOE4/4), we combine structured health experiments, expert access, pharmaceutical partnerships, and peer accountability to help members take control of their cognitive future.
